JP4671092B2 - ウイルス感染予防および対策 - Google Patents
ウイルス感染予防および対策 Download PDFInfo
- Publication number
- JP4671092B2 JP4671092B2 JP2003390695A JP2003390695A JP4671092B2 JP 4671092 B2 JP4671092 B2 JP 4671092B2 JP 2003390695 A JP2003390695 A JP 2003390695A JP 2003390695 A JP2003390695 A JP 2003390695A JP 4671092 B2 JP4671092 B2 JP 4671092B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- arginine
- virus
- viral infection
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000009385 viral infection Effects 0.000 title claims description 38
- 230000002265 prevention Effects 0.000 title description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 114
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 57
- 229930003268 Vitamin C Natural products 0.000 claims description 57
- 235000019154 vitamin C Nutrition 0.000 claims description 57
- 239000011718 vitamin C Substances 0.000 claims description 57
- 239000004475 Arginine Substances 0.000 claims description 44
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 44
- 241000700605 Viruses Species 0.000 claims description 31
- 208000036142 Viral infection Diseases 0.000 claims description 28
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 13
- 241000711573 Coronaviridae Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- 229960005486 vaccine Drugs 0.000 description 15
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 241001493065 dsRNA viruses Species 0.000 description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 7
- 230000036737 immune function Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000005422 blasting Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000008889 California Encephalitis Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014584 Encephalitis california Diseases 0.000 description 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 201000009908 La Crosse encephalitis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 201000005805 Murray valley encephalitis Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010059411 Prolonged expiration Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
した塩基配列をビタミンCに由来する前記の活性酸素ラジカルが攻撃し、それらの一部を切断する。また、寄生が終了すると、ウイルスは他の細胞に侵入するべく寄生していた細胞から脱出するが、この脱出時にもDNAやRNAが露出した状態が生じ、露出した塩基配列が活性酸素ラジカルによる攻撃を受ける。結果、これらの攻撃によりウイルスは死滅することとなり、感染が予防される。ラジカル攻撃による切断では、二本鎖より一本鎖の方がより容易に切断されやすいため、本発明の予防方法は、RNAウイルスに対してより有効であることが理解される。
1)経口投与の方法としては、所要量のビタミンCをジュース等の飲料約2Lに溶解させ、それを10回程度に分割して飲むのが都合が良い。但し、ビタミンCはジュースに溶解させると約90分間で50%が酸化体となって効果が減少するので、投与する直前にその都度溶解させることが好ましい、
2)ビタミンCには利尿作用が有るが、頻尿となっても問題はない、
3)ビタミンCの大量投与により尿管結石が生じると言う説が有ったが、現在は否定されている。ビタミンCの投与で酸性尿を呈するが、結石の原因となるカルシウムの沈殿は生じない、
4)ビタミンCを点滴により投与する場合には、点滴液のpHを6.5前後に調整する必要がある。pHが7.0以上となるとビタミンCの活性が低下する、
5)ビタミンCは常に自動酸化するので、従来はアミノ酸(シスチン、システイン)、グルタチオンで自動酸化を防いでいる。しかしながら、シスチンおよびシステインの大量投与はアミノ酸のインバランスをきたすので、大量投与におけるビタミンCの自動酸化の抑制には用いない方が良い、
6)大量のビタミンCの投与は、生体内のミネラル成分をキレート化し、低カリウム、低マグネシウム、低カルシウム等を引き起こすので、注意する必要がある。しかしながら、50g/日程度の投与量ではこの現象は生じることはない、
7)14C(アイソトープ)で標識したビタミンCを投与する動物実験では、14Cの70%は14CO2として呼気中に、また残る20%は尿中に排出される。大量のビタミンCを投与した場合、直ちに悉く尿中に***されるという通説は再考を要すると思われる。
インフルエンザ肺炎を被っている70歳の男性を対象とした。該対象の胸部X線写真には両側肺門部にbutter-fly様の陰影が観察され、肺炎を引き起こしていることが解った。また抗生物質の投与は無効であった。
該対象に、1000mg/kg/日のビタミンCと、3g/日のアルギニンとを投与した。
投与の結果、対象は4週間後には歩行可能となるまでに回復し、血中の酸素分圧も正常な値に戻った。
肺機能の低下した70歳代の男性を対象とした。該対象は常に酸素の吸入が必要で、上半身の視診により、胸骨上窩の吸気時の陥没が観察され、また聴診では呼吸音が弱く、呼
気相および呼出時間の延長が観察された。さらに胸部への打診では打鼓音を呈し、肺の過膨張が観察された。該対象の胸部CT所見では、肺気腫の症状である肺間質繊維の断裂による肺胞の拡大が随所に見られた。血液ガス分析でも、血中の酸素分圧が低下しており、肺における静脈血混合、即ち肺の酸素ガス交換に関与しない血液の動脈系への混合が推定された。
該対象に、1000mg/kg/日のビタミンCと、3g/日のアルギニンとを投与した。係るアルギニンの投与量では僅かな効果しか認められなかったため、尿中のNOx濃度を観察して、過剰のNOxが排出されないよう留意しつつアルギニンの投与量を徐々に増加させた。すると投与量を6g/日としたときに、十分な効果を達成した。このとき、十分な効果が達成されないならば、尿中に過剰のNOxが排出されない限り、アルギニンの投与量を例えば9g/日へとさらに増加させることもできる。
投与の結果、約1ヶ月後には酸素の吸入が不要となり、血中の酸素分圧が85以上、また二酸化炭素分圧が約40となって正常な値に近づいた。アルギニンの常用においても、尿中のNOx濃度は全く正常な値を示していた。
Claims (6)
- ビタミンC及びアルギニンを有効成分とするウイルス感染の予防剤であって、該ビタミンCについて少なくとも300〜500mg/kg/日の投与量であり、前記ウイルス感染のウイルスが、インフルエンザウイルス、ムンプスウイルス、麻疹ウイルス及びコロナウイルスからなる群より選択されることを特徴とするウイルス感染症の治療剤。
- アルギニンについて少なくとも3g/日の投与量である請求項1記載のウイルス感染症の治療剤。
- 経口投与剤である請求項1又は請求項2記載のウイルス感染症の治療剤。
- 前記ウイルスがインフルエンザ肺炎を引き起こすインフルエンザウイルスである請求項1ないし3のいずれか1項に記載のウイルス感染症の治療剤。
- 前記ウィルスがSARSを引き起こすコロナウイルスである請求項1ないし3のいずれか1項に記載のウイルス感染症の治療剤。
- コーティングで被覆したビタミンCとアルギニンとを含んでなる、請求項1ないし5のいずれか1項に記載のウイルス感染症の治療剤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003390695A JP4671092B2 (ja) | 2003-11-20 | 2003-11-20 | ウイルス感染予防および対策 |
PCT/JP2004/003215 WO2005049007A1 (ja) | 2003-11-20 | 2004-03-11 | ウイルス感染予防および対策 |
EP04719654A EP1693058A4 (en) | 2003-11-20 | 2004-03-11 | AGENT AND MEASURES FOR THE PREVENTION OF VIRAL INFECTION |
CA002547881A CA2547881A1 (en) | 2003-11-20 | 2004-03-11 | Prevention of and countermeasures against viral infection |
US12/385,667 US20090209640A1 (en) | 2003-11-20 | 2009-04-15 | Prevention of and countermeasures against viral infection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003390695A JP4671092B2 (ja) | 2003-11-20 | 2003-11-20 | ウイルス感染予防および対策 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005154283A JP2005154283A (ja) | 2005-06-16 |
JP2005154283A5 JP2005154283A5 (ja) | 2005-12-02 |
JP4671092B2 true JP4671092B2 (ja) | 2011-04-13 |
Family
ID=34616351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003390695A Expired - Fee Related JP4671092B2 (ja) | 2003-11-20 | 2003-11-20 | ウイルス感染予防および対策 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1693058A4 (ja) |
JP (1) | JP4671092B2 (ja) |
CA (1) | CA2547881A1 (ja) |
WO (1) | WO2005049007A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5656350B2 (ja) * | 2008-10-08 | 2015-01-21 | ポッカサッポロフード&ビバレッジ株式会社 | 抗sarsコロナウイルス剤及び抗sarsコロナウイルス作用促進方法 |
WO2022089677A1 (de) * | 2020-10-27 | 2022-05-05 | Gosbert Weth | Antivirale thrombosehemmende und tumorschädigende zusammensetzung mit arginin und thiocyanat |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA939265A (en) * | 1967-11-18 | 1974-01-01 | Yoshitaka Ikezuki | Injectable compositions for alleviating the pain incurred from administrations of injections |
JPS57100179A (en) * | 1980-12-16 | 1982-06-22 | Nissan Gosei Kogyo Kk | Mixing method of particulate or granular saccharide with amino acid |
JPS62221624A (ja) * | 1986-03-24 | 1987-09-29 | Shizuoka Pref Gov | 魚類のウイルス病予防.治療方法 |
DE3728367C1 (de) * | 1987-08-25 | 1988-09-01 | Burkhard Steglich | Mittel zur Immunisierung des menschlichen Koerpers bei HIV-Infektionen |
US6608109B2 (en) * | 1991-11-20 | 2003-08-19 | Allen Ann De Wees | Composition comprising L-arginine as a muscle growth stimulant and use thereof |
GB9318611D0 (en) * | 1993-09-08 | 1993-10-27 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
JPH10139683A (ja) * | 1996-11-14 | 1998-05-26 | Otsuka Pharmaceut Co Ltd | 免疫賦活栄養補給組成物 |
JP2000281575A (ja) * | 1999-03-25 | 2000-10-10 | Kyokuto Internatl Corp | 油脂被覆ビタミンc経口給与による、家畜の免疫力増強、並びにストレスの防除及び損耗を防止する方法 |
JP4601745B2 (ja) * | 1999-08-23 | 2010-12-22 | ハウスウェルネスフーズ株式会社 | 免疫賦活効果を相乗的に増強した製剤 |
WO2001015777A1 (en) * | 1999-08-31 | 2001-03-08 | Oxycal Laboratories, Inc. | Pulmonary-administration of mineral ascorbates |
US20020197352A1 (en) * | 2001-04-02 | 2002-12-26 | Pacifichealth Laboratories, Inc. | Sports drink composition for enhancing glucose uptake into the muscle and extending endurance during physical exercise |
DE10128910A1 (de) * | 2001-06-15 | 2002-12-19 | Beiersdorf Ag | Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung |
CN1164267C (zh) * | 2003-06-02 | 2004-09-01 | 中国科学院上海药物研究所 | 绿原酸的医学用途及它的制剂 |
CN1476836A (zh) * | 2003-06-10 | 2004-02-25 | 中国科学院上海药物研究所 | 紫锥松果菊提取物的抗sars作用及其药物组合物 |
-
2003
- 2003-11-20 JP JP2003390695A patent/JP4671092B2/ja not_active Expired - Fee Related
-
2004
- 2004-03-11 EP EP04719654A patent/EP1693058A4/en not_active Withdrawn
- 2004-03-11 WO PCT/JP2004/003215 patent/WO2005049007A1/ja active Application Filing
- 2004-03-11 CA CA002547881A patent/CA2547881A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005049007A1 (ja) | 2005-06-02 |
EP1693058A4 (en) | 2010-02-17 |
EP1693058A1 (en) | 2006-08-23 |
CA2547881A1 (en) | 2005-06-02 |
JP2005154283A (ja) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hill et al. | Evaluation of an interferon inducer in viral respiratory disease | |
CN107847430A (zh) | 一种具有抗病毒活性的鼻塞疏通组合物 | |
US20230190652A1 (en) | Composition for the treatment of covid-19 and treatment method | |
WO2023165566A1 (zh) | 治疗、预防由病毒感染引起的相关疾病的药物及其用途 | |
CN112135625A (zh) | 一种预防或治疗covid-19新冠肺炎的药物、食物及其应用 | |
EP1429712B1 (en) | Method for treating bronchial constriction and bronchospasm | |
JP2013508309A (ja) | 風邪およびインフルエンザの治療のためのショウガおよびアキノキリンソウを含む草本組成物 | |
JP4671092B2 (ja) | ウイルス感染予防および対策 | |
SI1407776T1 (sl) | Farmacevtski koloidni pripravek, ki vsebuje biopolimere hialuronske kisline, uporaben pri zdravljenju respiratornih bolezni | |
US20090209640A1 (en) | Prevention of and countermeasures against viral infection | |
JP7399976B2 (ja) | Covid-19新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 | |
US20230030607A1 (en) | Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases | |
WO2021255129A1 (en) | Novel use of a modulator of glucosylceramide degradation for viral infections | |
Hand et al. | Aerosolized pentamidine for prophylaxis of Pneumocystis carinii pneumonia in infants with human immunodeficiency virus infection | |
US20230226136A1 (en) | A synergistic formulation for management of respiratory pathogens including coronaviruses | |
Shahin | Suggested study as a treatment protocol for coronavirus | |
RU2266757C2 (ru) | Способ подавления коронавируса атипичной пневмонии | |
Polak | Respiratory syncytial virus (RSV): overview, treatment, and prevention strategies | |
WO2002005802A1 (fr) | Traitement de fond du rhume | |
WO2022112399A1 (en) | Compositions for the inactivation of sars-cov-2 | |
Sarkar et al. | Pathomechanism in SARS-CoV-2 infection in neurological, renal and respiratory systems: insights from the ground | |
JP2023143850A (ja) | コロナウイルス感染症予防用組成物 | |
CN112805027A (zh) | 一种抗新冠病毒感染的药物、食物与应用 | |
RU2054942C1 (ru) | Средство для профилактики и лечения гриппа | |
Jamshald | Evidence for the cure of flu through nose breathing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051018 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20051018 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20051110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051124 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060123 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060124 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060131 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070328 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070525 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070730 |
|
A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20071228 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100708 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101102 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101102 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110106 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140128 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |